Belantamab Mafodotin and Ocular Issues

Background of the study:

Belantamab mafodotin (GSK2857916; belamaf; BLENREP) is a B-cell maturation antigen (BCMA)-targeting antibody–drug conjugate approved in the US and by the European Union (EU) as a monotherapy for the treatment of adult patients with RRMM. Ocular events (OEs) during the pivotal DREAMM-2 trial (NCT03525678) included corneal exam findings (punctate keratopathy and microcyst-like epithelial changes), BCVA changes, and ocular symptoms. Dose reductions or delays based on corneal exam findings and BCVA were used to manage OEs. Here we performed a post hoc investigation of relationships between corneal exam findings, BCVA changes, and patient-reported ocular symptoms to explore if BCVA changes and symptoms could guide dosing, rather than corneal exams.

In this video:

Dr. Evengelos Terpos (National and Kapodistrian University of Athens, Athens, Greece) discusses the ocular symptoms in patients with relapsed or refractory multiple myeloma receiving belantamab mafodotin.

Conclusions:

These findings highlight that BCVA changes and ocular symptoms should be further investigated to determine if they can be used as alternatives (eg, frequency of eye examinations based on symptoms) for the management of belamaf dosing to potentially reduce the burden on patients and healthcare professionals. 

Clinical trial information: NCT03525678 (https://clinicaltrials.gov/ct2/show/NCT03525678)